Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][10]. Core Insights - The medical and biological sector experienced a decline of 3.31% this week, ranking 22nd among the 31 primary industries in the Shenwan index. The Shanghai and Shenzhen 300 index rose by 0.08%, indicating that the medical sector underperformed by 3.39 percentage points [2][12]. - The newly revised "Regulations on the Implementation of the Drug Administration Law" will take effect on May 15, 2026, aiming to enhance drug research, registration, and production management, thereby fostering innovation in the pharmaceutical industry [5][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 33.87X, with a Price-to-Book (PB) ratio of 3.43X, reflecting a decrease from the previous week [4][30]. Summary by Sections Industry Performance - The medical services sub-sector closed at 7122.75 points, down 4.15% this week, while the overall medical and biological sector fell by 3.31% [2][24]. - Notable performers in the medical services sector included Tigermed (+4.3%) and Prasis (+2.3%), while underperformers included Bid Pharma (-15.2%) and Haoyuan Pharma (-12.8%) [3][28]. Valuation Metrics - The medical services sector's PE ratio has decreased by 1.43X from the previous week, while the PB ratio has dropped by 0.15X [4][30]. - The maximum and minimum PE ratios over the past year were 41.13X and 28.46X, respectively, while the PB ratios ranged from 4.00X to 2.48X [30][49]. Regulatory Developments - The new drug administration regulations aim to support drug innovation and streamline the drug approval process, including provisions for market exclusivity for certain drugs [5][63]. - The regulations are expected to stimulate the CXO (Contract Research Organization) industry, enhancing demand for preclinical research and clinical trials [9][63]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO companies like WuXi AppTec and Haoyuan Pharma, as well as companies in the consumer healthcare sector like Aier Eye Hospital and Dian Diagnostics, which are expected to see improvements in profitability [10][64].

作为杭州市委市政府推进数据要素市场化改革的关键载体，杭州数据交易所有限公司（以下简称"杭数 所"）确立核心使命——超越传统数据交易平台定位，打造支撑人工智能时代新质生产力的数据基础设 施运营商。 "我们的优势在于不只做简单的数据买卖，而是在构建支撑新质生产力发展的数据要素供给体系。"杭数 所董事长兼总经理应琦在接受《中国经营报》记者专访时表示："杭数所的独特性，源自三重基因：一 是深度融入杭州人工智能战略的顶层设计，二是背靠杭州市金融投资集团与杭州市数据集团的双轮驱 动，三是首创'城市可信数据空间+高质量数据集+数据交易所'三位一体杭州范式。" 中经记者 石健 北京报道 2026年，"十五五"规划开局之年，杭州正全力冲刺"全国人工智能创新发展第一城"。在这场关乎未来产 业主导权的竞速中，数据不再是附属资源，而是决定智能体能力上限的核心生产要素。 依托这三重核心优势，杭数所在短短两年多时间里，从区域试点稳步迈向全国布局，成功打通数据全生 命周期的产业链路体系。 服务人工智能第一城 2025年6月，《杭州市加快建设人工智能创新高地实施方案（2025年版）》正式印发，明确提出"加快建 设具有全球竞争力和影响力的人工 ...

Group 1 - The core index of the biotechnology sector (970038) closed at 2205.04 points, down 0.85%, with a trading volume of 33.22 billion yuan and a turnover rate of 3.61% [1] - Among the constituent stocks, 10 companies experienced an increase, with Tigermed leading the gain at 6.96%, while 40 companies saw a decline, with Dian Diagnostics leading the drop at 4.63% [1] Group 2 - The net outflow of main funds from the biotechnology index constituent stocks totaled 69.18 million yuan, while the net inflow of speculative funds was 134 million yuan, and the net outflow of retail funds was 64.63 million yuan [2] - Detailed fund flow information for the constituent stocks is available in the accompanying table [2]

Group 1 - The core viewpoint of the article indicates that the precision medicine sector experienced a rise of 1.14% on January 29, with Di'an Diagnostics leading the gains [1] - The Shanghai Composite Index closed at 4157.98, reflecting an increase of 0.16%, while the Shenzhen Component Index closed at 14300.08, showing a decrease of 0.3% [1] - The net inflow of main funds into the precision medicine sector was 25.03 million yuan, while retail funds saw a net inflow of 69.95 million yuan, contrasting with a net outflow of 94.98 million yuan from speculative funds [1] Group 2 - The article provides a detailed overview of the fund flow within the precision medicine sector, highlighting the contrasting movements of different types of investors [1] - The data presented is based on publicly available information and generated by AI algorithms, indicating a reliance on technology for market analysis [1]

1月29日上午，医疗器械板块再迎催化，脑机接口领域接连获2项重大标准立项。截至发稿，含"脑"量约 24%的医疗器械指数ETF（159898）盘中上涨0.88%、一度涨超1%；权重股奕瑞科技大涨6.61%，乐普 医疗涨超3%，成份股迪安诊断涨超7%，美好医疗、金域医学涨超5%，华大基因、祥生医疗等多股拉 升。 消息面上，1月28日消息，为满足监管急需，助推采用脑机接口技术的医疗器械高质量发展，经研究， 国家药监局批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功能重建》《采用脑机接口技 术的医疗器械侵入式设备可靠性验证方法》等2项医疗器械行业标准制修订项目立项。 业内对此指出，这是对工信部等七部门此前发布的《关于推动脑机接口产业创新发展的实施意见》中标 准体系建设相关内容的具体落实，同时也结合行业反馈的共性难题实现了空白填补。 该机构分析强调，中证全指医疗器械指数精选103只成分股，重点聚焦创业板和科创板，覆盖医疗设 备、医疗耗材和体外诊断三大方向；指数质地纯粹，100%聚焦医疗器械细分板块，β属性纯正。"脑机 接口"概念暴露度达23.79%，对前沿医疗科技具备较好的布局优势；同时，指数成分股境外业务收入 ...

1月29日上午，医疗器械板块再迎催化，脑机接口领域接连获2项重大标准立项。截至发稿，含"脑"量约24%的医疗器械指数ETF（159898）盘中上涨 0.88%、一度涨超1%；权重股奕瑞科技大涨6.61%，乐普医疗涨超3%，成份股迪安诊断涨超7%，美好医疗、金域医学涨超5%，华大基因、祥生医疗等多股 拉升。 消息面上，1月28日消息，为满足监管急需，助推采用脑机接口技术的医疗器械高质量发展，经研究，国家药监局批准《采用脑机接口技术的医疗器械范式 设计与应用规范运动功能重建》《采用脑机接口技术的医疗器械侵入式设备可靠性验证方法》等2项医疗器械行业标准制修订项目立项。 业内对此指出，这是对工信部等七部门此前发布的《关于推动脑机接口产业创新发展的实施意见》中标准体系建设相关内容的具体落实，同时也结合行业反 馈的共性难题实现了空白填补。 此外，医疗器械指数ETF（159898）第四大权重股乐普医疗1月28日公告称，预计2025年归属于上市公司股东的净利润为8亿元-12亿元，比上年同期增长 223.97%-385.95%。主要因心血管植介入业务稳增、创新药及皮肤科等新兴板块贡献增量等。 万联证券指出，目前脑机接口正处于" ...

Industry Overview - The pharmaceutical and biotechnology sector experienced a decline of 0.39% last week, ranking 27th among 31 primary industries in the Shenwan index. The CSI 300 index fell by 0.62%, indicating that the pharmaceutical sector outperformed the CSI 300 by 0.23 percentage points [3] - The medical services sub-sector reported a drop of 2.17%, while other sub-sectors such as traditional Chinese medicine and medical commercial showed positive growth [3] Company Performance - Notable performers in the medical services sector included: - Nuohe Zhiyuan (+11.5%) - Xin Licheng (+9.4%) - Dian Diagnostics (+8.2%) - ST Zhongzhu (+7.1%) - Guangzheng Eye Hospital (+6.2%) - Underperformers included: - Boteng Co. (-6.9%) - Chengda Pharmaceutical (-6.6%) - WuXi AppTec (-6.4%) - Mediso (-4.8%) - Chengdu Xian Dao (-4.5%) [4] Financial Metrics - The medical services sector's Price-to-Earnings (PE) ratio is 35.30X, with a one-year maximum of 41.13X and a minimum of 28.46X. The Price-to-Book (PB) ratio stands at 3.58X, with a one-year maximum of 4.00X and a minimum of 2.48X. The PE ratio decreased by 0.85X and the PB ratio decreased by 0.09X compared to the previous week [6] CXO Industry Insights - The J.P. Morgan Healthcare Conference highlighted an optimistic outlook for the CXO industry, with companies like WuXi AppTec and WuXi Biologics showcasing strong growth prospects. The industry is transitioning from scale competition to value competition, focusing on advanced technologies and global supply chains. Notably, ADC CDMO is expected to drive significant revenue growth [7] Investment Recommendations - The report maintains a "buy" rating for the medical services sector, emphasizing the importance of innovation in the pharmaceutical supply chain. Key areas of focus include: - High growth: Companies involved in ADC CDMO and peptide CDMO, such as WuXi AppTec and Hao Yuan Pharmaceutical - Expected improvement: Third-party testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry, such as Aier Eye Hospital and Dian Diagnostics [8]

迪安诊断技术集团股份有限公司（以下简称"公司"）于近日接到公司控股 股东陈海斌先生通知，获悉其将持有的公司部分股份办理了质押，相关质押手续 已办理完毕。具体事项如下： 注：如本表格中数据加总后与数据汇总数存在尾差情况，系数据计算时四舍五入造成。 二、股东所持股份累计被质押的情况 截至公告披露日，控股股东陈海斌先生及其一致行动人杭州迪安控股有限公 司所持质押股份情况如下： 证券代码：300244 证券简称：迪安诊断 公告编号：2026-005 迪安诊断技术集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质押 | 本次质押 | | | 情况 | | 情况 | | | | | | | | 占其所 | 占公司 | | | | | | 股东 | 持股数量 | 持股 | 前质押股 | 后质押股 | ...

（文章来源：每日经济新闻） 1月28日医疗器械板块震荡调整，之江生物、万孚生物、迪安诊断、圣湘生物、三友医疗跌幅超5%，医疗器械ETF（562600）下跌2.18%。 从指数月线位置来看，医疗器械指数当前处在上一波熊牛转换起点附近，价格仍属相对低位，建议逢低关注。 ...

Core Viewpoint - The company, Dian Diagnostics, expects to achieve a net profit attributable to shareholders of 28 million to 42 million yuan in 2025, marking a turnaround from losses, with a net profit excluding non-recurring gains and losses projected at 10 million to 15 million yuan, also indicating a return to profitability [1] Group 1: Financial Performance - The company anticipates a significant improvement in net profit for 2025, with projections indicating a return to profitability compared to previous years [1] - Operating cash flow is expected to increase to approximately 1.8 billion yuan, reflecting a positive trend in operational efficiency [1] Group 2: Strategic Initiatives - In 2025, the company will officially launch a new five-year strategic plan, positioning itself as a leader in "intelligent solutions for medical diagnostics" [1] - The company aims to leverage "AI + big data" as its technological engine, focusing on creating an integrated ecosystem that combines research and development, diagnostic services, and health management [1] Group 3: Operational Focus - The company is concentrating on enhancing operational quality by targeting high-value clients and strengthening the promotion of specialized tests and proprietary products [1] - There is a steady increase in the number of new clients, indicating a solid market presence and operational growth [1] Group 4: Innovation and Technology - The company is accelerating the commercialization of AI products and has made significant progress in data operations, obtaining three types of medical device registrations, and expanding overseas business [1] - These advancements are expected to inject strong new momentum into the company's high-quality development [1]